Neuphoria Therapeutics (NASDAQ:NEUP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Neuphoria Therapeutics (NASDAQ:NEUP) to a hold rating in a research report released on Saturday.

A number of other equities analysts have also recently issued reports on NEUP. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Stock Up 5.8%

Neuphoria Therapeutics stock opened at $3.85 on Friday. Neuphoria Therapeutics has a 12-month low of $3.19 and a 12-month high of $21.40. The firm’s fifty day moving average is $4.27 and its 200 day moving average is $4.39. The company has a market capitalization of $20.79 million, a PE ratio of -0.35 and a beta of 0.74.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. Sell-side analysts expect that Neuphoria Therapeutics will post -4.07 EPS for the current fiscal year.

Institutional Trading of Neuphoria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AdvisorShares Investments LLC raised its holdings in Neuphoria Therapeutics by 15.8% during the first quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after buying an additional 21,173 shares during the last quarter. Diadema Partners LP grew its holdings in shares of Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock valued at $194,000 after buying an additional 28,548 shares during the last quarter. Ikarian Capital LLC bought a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $184,000. ADAR1 Capital Management LLC bought a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $116,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Neuphoria Therapeutics in the 4th quarter worth about $102,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.